13F Holdings
中文EN

PRME Prime Medicine, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%

Returns

ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.63M$2.98M$0$0$0
R&D expense$160.64M$155.29M$147.91M$86.72M$70.55M
SG&A expense$52.35M$50.16M$43.39M$29.82M$13.92M
Operating income-$208.35M-$202.47M-$204.79M-$116.54M-$84.47M
Income tax$0$0-$279,000-$948,000-$486,000
Net income-$201.14M-$195.88M-$198.13M-$121.82M-$165.37M
EBITDA-$201.03M-$196.34M-$200.14M-$114.32M-$83.91M
EPS (basic)-1.35-1.65-2.18-4.19-14.19
EPS (diluted)-1.35-1.65-2.18-4.19-14.19
Weighted avg. shares (diluted)148.76M118.60M90.97M33.89M12.97M
Balance sheet
Cash & equivalents$63.03M$196.54M$55.07M$201.12M$198.54M
Short-term investments$114.65M——$98.47M$68.24M
Current assets$181.29M$211.89M$142.98M$296.62M$270.58M
PP&E, net$20.57M$24.40M$22.66M$19.01M$4.93M
Total assets$342.73M$297.51M$193.85M$360.31M$301.86M
Current liabilities$37.45M$37.96M$56.42M$26.71M$57.98M
Total liabilities$221.87M$144.36M$60.78M$44.04M$62.30M
Shareholders' equity$120.87M$153.15M$133.07M$316.27M-$156.24M
Shares outstanding180.51M131.16M97.38M97.21M32.41M
Cash flow statement
Operating cash flow-$162.56M-$122.86M-$165.41M-$131.83M-$34.08M
Capital expenditure$4.53M$7.29M$8.72M$16.09M$4.15M
Free cash flow-$167.09M-$130.16M-$174.14M-$147.92M-$38.23M
Investing cash flow-$108.76M$68.46M$18.71M-$47.10M-$73.63M
Financing cash flow$151.51M$195.88M$655,000$181.49M$269.28M
Depreciation & amortization$7.32M$6.13M$4.65M$2.22M$568,000
Stock-based compensation$29.27M$26.07M$13.91M$6.46M$1.75M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.